Latest Funding News

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

Enlitic, Inc. reported a sharp revenue increase driven by migration services and subscription growth, while sustaining a net loss of US$6.86 million in H1 2025. The company secured a binding MOU with GE Healthcare and completed a A$10 million capital raise.

Savannah Goldfields Limited has announced a $15 million equity raising through a placement and conditional placement, offering free attaching options subject to shareholder approval. The capital raise aims to strengthen the company’s financial position and support its operational restart plans.

Nova Eye Medical Limited reported a 25% increase in revenue to AUD 29.3 million for FY2025, driven by strong sales in its glaucoma surgical devices segment, yet posted a net loss after tax of AUD 9.1 million. The company raised AUD 6.2 million through a share placement to support growth initiatives.

Mayfield Group Holdings Ltd has reported a landmark financial year with revenues soaring nearly 38% and profits climbing over 32%, driven by strong demand in Data Centres and AI infrastructure sectors.

US Masters Residential Property Group reported a modest portfolio valuation decline amid New York market uncertainty but maintained strong sales momentum and improved net operating income in Q2 2025.

US Masters Residential Property Group reports a half-year profit and advances its ambitious asset sales program, while navigating a significant US tax structure change and mixed market conditions.

Global Health Limited reported a reduced net loss for FY2025, driven by growing subscription revenue and strategic AI integration as it transitions to a SaaS platform.

N1 Holdings reported a 6.8% revenue increase to $19.69 million for FY25, while net profit fell 21.1% to $855,826. The company advanced AI initiatives and expanded lending capacity, signaling strategic growth despite profit pressures.

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.

Ark Mines reports its Stage-3 drilling at Sandy Mitchell is ahead of schedule, aiming to nearly quintuple its measured mineral resource and fuel a pivotal Pre-Feasibility Study.

Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.